R&D and Innovation

ANNTOMMED holds an independent portfolio of patents and software copyrights covering its interventional product lines — balloon inflation devices, hemostasis valve sets, guide wires, angiographic syringes, introducer sets, manifolds and stopcocks — with intellectual property management integrated into the development process under our EN ISO 13485:2016 quality system.

ANNTOMMED holds an independent portfolio of patents and software copyrights covering its interventional product lines — balloon inflation devices, hemostasis valve sets, guide wires, angiographic syringes, introducer sets, manifolds and stopcocks — with intellectual property management integrated into the development process under our EN ISO 13485:2016 quality system.

ANNTOMMED carries out R&D in-house at its own production base in the Zhongkai High-Tech Zone, Huizhou — a 3,000 m² facility with more than 1,000 m² of cleanrooms — supported by an engineering team of experienced researchers, professional technicians and medical expert consultants. Our development covers interventional device design, high-pressure fluid-path engineering and clinical evaluation support, and runs under an EN ISO 13485:2016 quality management system aligned with EU MDR requirements. As a national high-tech enterprise, we are committed to developing world-class medical devices for cardiovascular intervention.

Over the years, our company has maintained a strong focus on technological innovation driven by clinical needs and is dedicated to developing quality medical device products.

Our Intellectual Property Management System safeguards our scientific and technological breakthroughs and fosters ongoing research and development.